Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma
Source: PMLive, July 2024
Bristol Myers Squibb (BMS) has announced that its new immunotherapy combination, Opdualag (nivolumab-relatlimab), has been accepted by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for advanced melanoma.
Providing an additional treatment option for eligible patients in Scotland living with the form of skin cancer, the first approved LAG-3 blocking antibody combination is indicated as a first-line treatment in adults and adolescents 12 years of age and older living with the disease.
Currently the fifth-most common cancer in the UK, melanoma is a type of skin cancer that develops when pigment-producing cells located in the skin grow uncontrollably.